• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喹那普利在老年患者中的应用。

Use of quinapril in the elderly patient.

作者信息

Schnaper H W

机构信息

University of Alabama, Birmingham 35294.

出版信息

Am J Hypertens. 1990 Nov;3(11):278S-282S. doi: 10.1093/ajh/3.11s.278s.

DOI:10.1093/ajh/3.11s.278s
PMID:2261146
Abstract

Quinapril hydrochloride is a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor that has been extensively tested and found effective when administered once-a-day to hypertensive patients of both sexes and all degrees of hypertension and cardiac compromise, including those with left ventricular hypertrophy, with and without congestive heart failure. Observations with earlier ACE inhibitors led to reports that this class of drugs was relatively ineffective in older hypertensive patients. To ascertain the role of quinapril (greater than or equal to 10 mg/day) in older patients, its blood pressure-lowering effects in 1,175 hypertensive patients less than or equal to 65 years of age were compared with those in 304 patients greater than 65 years of age. An excellent response was observed in patients greater than 65 years of age with mild to moderate hypertension (diastolic BP, 95 to 105 mm Hg) and moderate to severe hypertension (diastolic BP, 106 to 115 mm Hg). The reductions in blood pressure achieved with quinapril were at least comparable to those obtained in the younger hypertensives, and were numerically (but not statistically) greater in the mild to moderate group (-14 mm Hg v-12 mm Hg). In addition, the percentage of patients who experienced adverse experiences was lower in the greater than 65 group than in the less than or equal to 65 group (15% v 19%). The main adverse experiences reported included dizziness, headache, cough, fatigue, and hypotension. These findings indicate that quinapril is at least as safe and effective in older hypertensives as in younger patients.

摘要

盐酸喹那普利是一种非巯基血管紧张素转换酶(ACE)抑制剂,已进行了广泛测试,结果表明,对于患有各种程度高血压和心脏损害的男女高血压患者,包括伴有或不伴有充血性心力衰竭的左心室肥厚患者,每日服用一次该药均有效。早期对ACE抑制剂的观察结果导致有报告称,这类药物在老年高血压患者中相对无效。为了确定喹那普利(大于或等于10毫克/天)在老年患者中的作用,将其在1175名年龄小于或等于65岁的高血压患者中的降压效果与304名年龄大于65岁的患者进行了比较。在年龄大于65岁的轻度至中度高血压(舒张压95至105毫米汞柱)和中度至重度高血压(舒张压106至115毫米汞柱)患者中观察到了良好的反应。喹那普利实现的血压降低至少与年轻高血压患者相当,在轻度至中度组中数值上(但无统计学意义)更大(-14毫米汞柱对-12毫米汞柱)。此外,年龄大于65岁组中出现不良事件的患者百分比低于年龄小于或等于65岁组(15%对19%)。报告的主要不良事件包括头晕、头痛、咳嗽、疲劳和低血压。这些发现表明,喹那普利在老年高血压患者中至少与年轻患者一样安全有效。

相似文献

1
Use of quinapril in the elderly patient.喹那普利在老年患者中的应用。
Am J Hypertens. 1990 Nov;3(11):278S-282S. doi: 10.1093/ajh/3.11s.278s.
2
Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril.血管紧张素转换酶抑制剂作为重度高血压的初始单一疗法。喹那普利和卡托普利。
Am J Hypertens. 1991 Oct;4(10 Pt 1):827-31. doi: 10.1093/ajh/4.10.827.
3
Efficacy and safety of quinapril in the elderly hypertensive patient.喹那普利在老年高血压患者中的疗效与安全性。
Am Heart J. 1992 May;123(5):1426-32. doi: 10.1016/0002-8703(92)91065-9.
4
Quinapril: a double-blind, placebo-controlled trial in essential hypertension.
Angiology. 1989 Apr;40(4 Pt 2):370-81. doi: 10.1177/000331978904000406.
5
Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.喹那普利在健康志愿者、高血压患者及充血性心力衰竭患者中的临床药理学。
Angiology. 1989 Apr;40(4 Pt 2):360-9. doi: 10.1177/000331978904000405.
6
Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.喹那普利。对其在心血管疾病中的药理学和治疗效果的重新评估。
Drugs. 1994 Aug;48(2):227-52. doi: 10.2165/00003495-199448020-00008.
7
The safety profile of quinapril: is there a difference among ACE inhibitors?喹那普利的安全性概况:血管紧张素转换酶抑制剂之间存在差异吗?
Clin Cardiol. 1990 Jun;13(6 Suppl 7):VII39-42. doi: 10.1002/clc.4960131408.
8
The management of hypertension in older patients.
J Cardiovasc Pharmacol. 1990;15 Suppl 2:S56-61. doi: 10.1097/00005344-199000152-00010.
9
Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.喹那普利:其在心血管疾病中的药理学及治疗应用的进一步更新
Drugs. 2002;62(2):339-85. doi: 10.2165/00003495-200262020-00009.
10
A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.对3742例加拿大高血压患者进行的喹那普利上市后监测评估:ACCEPT研究。喹那普利加拿大临床评估与患者教育。
Clin Ther. 1994 Sep-Oct;16(5):838-53.

引用本文的文献

1
Optimal dosage of ACE inhibitors in older patients.老年患者中血管紧张素转换酶抑制剂的最佳剂量
Drugs Aging. 1996 Oct;9(4):262-73. doi: 10.2165/00002512-199609040-00004.
2
ACE inhibitors. Differential use in elderly patients with hypertension.血管紧张素转换酶抑制剂。老年高血压患者的差异使用情况。
Drugs Aging. 1995 Nov;7(5):355-71. doi: 10.2165/00002512-199507050-00004.
3
Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.喹那普利。对其在心血管疾病中的药理学和治疗效果的重新评估。
Drugs. 1994 Aug;48(2):227-52. doi: 10.2165/00003495-199448020-00008.